Previous 10 | Next 10 |
The Hague, April 4, 2023 - Aegon announces today the sale of its UK individual protection book to Royal London. The transaction supports Aegon’s strategy to focus on the core Retail and Workplace platform activities in the United Kingdom, as part of the ambition to create leading businesse...
(NewsDirect) Argenica Therapeutics Ltd (ASX: AGN) CEO Liz Dallimore speaks with Proactive from the ASX Small and Mid-Cap Conference March 2023. The company is developing novel therapeutics to reduce brain tissue death after stroke and other types of brain injury and neurodegenerative diseases...
The Hague, March 16, 2023 - Aegon N.V. today published its Integrated Annual Report 2022. The report provides an overview of its businesses, the company’s strategy and sustainability approach, and its financial and non-financial performance. The report also reflects on the key trends that ...
The Hague, March 9, 2023 - Aegon will today host an educational webinar to outline its implementation of the accounting standards IFRS 17 and IFRS 9, which have become effective on January 1, 2023. IFRS 17 is the first international accounting standard for insurance contracts and aims to create m...
Toronto, Ontario--(Newsfile Corp. - Le 1 mars/March 2023) - Algernon Pharmaceuticals Inc. has announced a four (4) for one (1) stock split of its issued and outstanding common shares. Each shareholder of record as of the close of business on the record date will receive three (3) additional share...
Please click here to access all 4Q2022 results related documents. The Hague, February 9, 2023 - Acceleration of strategy execution and delivery on financial commitments Previously announced impairment loss from classifying Aegon the Netherlands as held for sale follo...
The Hague, January 17, 2023 - Aegon N.V.'s Extraordinary Meeting of Shareholders (EGM) has today approved the strategic decision to combine Aegon’s Dutch pension, life and non-life insurance, banking, and mortgage origination operations with a.s.r. to create a leading player in the Dutch m...
VANCOUVER, BC / ACCESSWIRE / January 9, 2023 / The Power Play by The Market Herald has announced the release of a new interview with Algernon Pharmaceuticals discussing their latest news. The Power Play by The Market Herald provides investors with a quick snapshot of what they need to know abou...
The Hague, July 1, 2022 - Aegon will repurchase common shares for an amount of EUR 106 million to neutralize the dilutive effect of the 2021 final dividend paid in shares . These shares will be held as treasury shares and will be used to pay future stock dividends ...
The Hague, May 31, 2022 - Aegon N.V.’s Annual General Meeting (AGM) today approved all resolutions on the agenda, including adoption of the Annual Accounts for the financial year 2021 and a final dividend for 2021 of EUR 0.09 per common share, bringing Aegon’s total dividend f...
News, Short Squeeze, Breakout and More Instantly...
2024-03-27 17:08:02 ET About to begin a phase 2b/3 multinational study of Ifenprodil Algernon Pharmaceuticals is a drug repurposing company. They're a phase 2 clinical stage company advancing a drug called Ifenprodil for idiopathic pulmonary fibrosis, but also as a potential thera...
2024-03-27 17:08:02 ET A stroke can be a devastating and debilitating event for an individual and their family, and a major burden on the health care system. Over 15 million people suffer strokes every year, and 85% of those have some form of disability as a result. Stroke-related cos...
2024-03-27 17:08:02 ET Stocks to Invest in: Healthcare Focused on the disease areas of stroke, idiopathic pulmonary fibrosis (IPF) & chronic cough, and chronic kidney disease Algernon is a drug re-purposing company that investigates safe, already approved drugs, inclu...